Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage?

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 45

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

1197

HTML

12822

Figures (1-3)

157

Tables (1-2)

168

Sum=14344

Dec 7, 2010 (publication date) through Apr 22, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Dec 7, 2010; 16(45): 5651-5661
Published online Dec 7, 2010. doi: 10.3748/wjg.v16.i45.5651

Figure 1 Piroxicam induced hepato-canalicular cholestasis associated with ductopenia (notice absence of bile duct in the portal tract).

Figure 2 Latency (time from nimesulide intake to clinical onset) in 43 patients.

Figure 3 Acute hepatitis induced by nimesulide (hepatocellular collapsed areas are shown with arrows).

Citation: Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol 2010; 16(45): 5651-5661
URL: https://www.wjgnet.com/1007-9327/full/v16/i45/5651.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i45.5651